22 related articles for article (PubMed ID: 3461178)
1. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
[TBL] [Abstract][Full Text] [Related]
2. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
3. [Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
Ohshima A; Yoshida K; Miyazaki S; Fukushima Y; Miura AB; Endo K; Ando H; Sasaki H; Saito S; Sato I
Gan To Kagaku Ryoho; 1989 Jan; 16(1):139-42. PubMed ID: 2643393
[No Abstract] [Full Text] [Related]
4. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy].
Hirota Y; Shibuya T; Ohhara N; Okamura S; Iwagiri R; Tada Y; Otsuka T; Nagano M; Tsuda Y; Niho Y
Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812
[No Abstract] [Full Text] [Related]
5. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
Willemze R; Fibbe WE; Zwaan FE
Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
[No Abstract] [Full Text] [Related]
6. High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia.
Cole N; Gibson BE
Blood Rev; 1997 Mar; 11(1):39-45. PubMed ID: 9218105
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukaemia in the elderly: biology and treatment.
Johnson PR; Liu Yin JA
Br J Haematol; 1993 Jan; 83(1):1-6. PubMed ID: 7679585
[No Abstract] [Full Text] [Related]
8. Acute myeloid leukemia followed by hepatic leiomyosarcoma. A case report.
Príncipe F; Ferreira JS; Sobrinho-Simões M
Acta Med Port; 1988; 1(1):87-9. PubMed ID: 3061284
[No Abstract] [Full Text] [Related]
9. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
[No Abstract] [Full Text] [Related]
10. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results.
Stasi R; Venditti A; Del Poeta G; Aronica G; Abruzzese E; Pisani F; Cecconi M; Masi M; Amadori S
Leuk Res; 1996 Jul; 20(7):535-49. PubMed ID: 8795687
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
